# A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Source: https://onco.cc/trials/nct06769152/  
OnCo record `nct06769152` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of HLX43 in cervical cancer and ovarian cancer, run by Shanghai Henlius Biotech, now recruiting.

## Summary

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors is a phase 2 interventional study registered as NCT06769152 by Shanghai Henlius Biotech, with 190 participants planned, started 2025-02-20 and due to reach its primary completion in 2026-12-31. Interventions recorded: HLX43. Conditions listed: Cervical Cancer, Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06769152
- Phase: 2
- Setting: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Recurrent/Metastatic Gynecological Malignant Tumors Failed or Intolerance to Standard First-Line Therapy
- Sponsor: Shanghai Henlius Biotech
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT06769152: https://clinicaltrials.gov/study/NCT06769152

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [HLX43](https://onco.cc/drugs/hlx43/)
- companies: [Shanghai Henlius Biotech](https://onco.cc/companies/henlius/)

---
JSON: https://onco.cc/api/v1/entities/nct06769152.json